Protalix BioTherapeutics arrives at its Q1 results day with a dramatic revenue beat already on the tape — yet the stock's month-long slide and a sharp defensive tilt in options suggest the market is still far from convinced.
Q1 revenue came in at $33.75M, demolishing the Street's $11.47M estimate. The headline driver was a $25M Elfabrio milestone payment that pulled the quarter's numbers well above consensus. EPS landed at $0.22 on a corrected basis, also ahead of the $0.06 estimate. Management reaffirmed its 2026 revenue outlook of $78M–$83M, and the 10-Q filed this morning confirms the quarter is clean. On its face, the beat is material. The stock's subdued reaction — down roughly 1.5% on the day and off 17% over the past month to $1.91 — signals that investors are treating the milestone as non-recurring and looking past it to the underlying commercial run-rate.
Options positioning captures that scepticism precisely. The put/call ratio climbed to 0.25, the highest reading of the past year, and the z-score against the 20-day average reached 2.5 standard deviations — the clearest defensive lean the options market has shown on this name in at least twelve months. The move stands out because PLX options are thin; it doesn't take much volume to shift the PCR meaningfully, but reaching a 52-week high on earnings day is a telling signal about how traders were positioned into the print.
Short positioning adds to the cautious picture. Short interest edged up roughly 4.5% on the week to 6.1% of free float — a level that is not extreme for a small-cap biotech, but the direction of travel matters. The month-on-month build of about 2.3% shows gradual accumulation rather than a sudden conviction bet. Borrowing costs remain negligible at 0.61% annualised, and availability is wide at roughly 289% of short interest, meaning there is no meaningful friction preventing fresh shorts from entering. The borrow market is loose; the squeeze pressure is close to zero.
The sole analyst covering the stock publicly — HC Wainwright — has maintained a Buy with a $12.00 target since at least March 2026, a level that implies more than 500% upside to the current $1.91 price. That gap is too wide to treat as an actionable signal at face value and likely reflects a structural mismatch between a boutique coverage thesis built on full pipeline optionality and a market that is repricing the stock on near-term cash generation. The ORTEX short score edged to 57.7 this week, up from the mid-50s range where it has held for several weeks. Factor scores are broadly mid-table: short score ranks at the 27th percentile of the universe, days-to-cover at the 35th.
On the institutional side, MAK Capital One entered the register in the March quarter with a full new position of 3.6M shares — roughly 4.5% of the company — one of the more notable accumulation moves in the cap table. BlackRock added modestly in the same period. Neither offsets the weight of what the options and price action are saying, but the MAK entry provides at least one active manager with a visible long catalyst thesis.
The March quarter earnings event offers the only available price-reaction data point: the stock fell 20% the next day and 22.5% over five days after the previous release. That print saw no milestone payment and landed poorly. This quarter's print is structurally different — revenue beats by nearly 3x — yet the intraday price response is barely distinguishable from flat. Whether the market's indifference to today's beat reflects accurate discounting of milestone lumpiness or a deeper concern about the underlying Elfabrio revenue trajectory is the question that the coming weeks of short interest data and any follow-on analyst commentary will either resolve or deepen.
See the live data behind this article on ORTEX.
Open PLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
